Recent major news for Fulcrum Therapeutics centers around its definitive all-stock merger agreement with Slate Medicines to advance a specialized pipeline of next-generation migraine therapies, alongside a concurrent oversubscribed private placement financing of $245 million designed to fund operations into the year 2029. Under the terms of the transaction, the combined entity will operate under the name Slate Medicines, Inc. and trade on the Nasdaq under the ticker symbol SLTE. Prior to closing, Fulcrum also announced plans to distribute a pre-closing cash dividend to its existing stockholders.